Skip to main content
Figure 5 | Breast Cancer Research

Figure 5

From: Are we HER-ting for innovation in neoadjuvant breast cancer trial design?

Figure 5

GeparQuinto study design for HER2-positive cohort. C, cyclophosphamide (600 mg/m2: day 1 q day 21 for four cycles); E, epirubicin (90 mg/m2: every 3 weeks for four cycles); H, trastuzumab (8 mg/kg: loading dose, 6 mg/kg: every 3 weeks); Her-2, human epidermal growth factor receptor 2; L, lapatinib (1,250 mg daily for 24 weeks: run-in phase cycles 1 and 5: 1,000 mg daily); R, randomisation; T, docetaxel (100 mg/m2: every 3 weeks for four cycles). Reprinted with permission from GBG (German Breast Group).

Back to article page